Retatrutide vs Tirzepatide: What's the Difference?

Not legally outside a clinical trial. The compound is investigational; FDA approval and commercial availability are projected for 2026–2027.

Too early to say. Phase 2 side-effect profiles look similar (GI nausea, vomiting, diarrhea), but long-term safety data won't exist until Phase 3 reads out.

Compounded semaglutide programs average $149–$299/month all-in. Tirzepatide compounded programs typically run $299–$499/month. Branded Wegovy and Zepbound run higher unless covered by insurance.

The active ingredients are FDA approved; compounded formulations are not separately FDA approved. They are dispensed by state-licensed 503A or federally-registered 503B pharmacies regulated by the FDA.

Most patients see appetite suppression within the first 1–2 weeks and 1–2% body-weight reduction per month once titrated to therapeutic dose (typically week 8–12).

Most patients regain weight after stopping unless they continue lifestyle changes, sometimes paired with a maintenance dose. The best clinics include a transition plan in their program.

Generally yes, but oral medications may be absorbed more slowly. Always disclose your full medication list during intake — your clinician will adjust timing where needed.